LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$81.89 USD
+0.01 (0.01%)
Updated Jun 26, 2024 03:59 PM ET
After-Market: $81.90 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Brokerage Reports
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 1 - 20 ( 191 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Resuming Coverage - Initiating Coverage
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Optimized Entry and Exit Levels for LMAT 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Medical Technology: Suspending Coverage of 21 Companies
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
1Q23 Recap - Hitting on All Cylinders (Volume/Price)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S